FAGRON
Fagron NV delivers personalized pharmaceutical care globally through three segments: Essentials, Brands, and Compounding Services. The company innovates products and formulations for compounding. Its products include various excipients, phytocomplexes, and pharmaceuticals for skin, hair, and immune system treatment. Fagron also offers education and training programs through the Fagron Academy.
Overview
Strengths
- Current Price to Earnings Ratio (19.80) is lower than the sector mean (289.29).
- EV/EBIT (16.56) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -34.66%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (2.57) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (10.59%) is significantly lower than the sector mean (14.71%).
Key Financial Data
| Indicator | Value |
|---|
| PER | 19.8 |
| EV/EBITDA | 12.3 |
| Price/Free Cash Flow' | 23.1 |
| ROIC | 10.6% |
| Net Debt/EBITDA | 2.6 |